Literature DB >> 8720030

The effect of clozapine on self-injurious behavior.

R G Hammock1, S R Schroeder, W R Levine.   

Abstract

Traditional neuroleptic drugs like thioridazine and haloperidol have not proven to be systematically effective with the treatment of self-injurious behavior (SIB). These drugs may be ineffective because they primarily block D2 dopamine receptors. Based on research with humans and other animals, it appears that another dopamine receptor, D1, may be responsible for mediating some SIB. Clozapine, a neuroleptic recently introduced in the United States, has proven effective in treatment of refractory cases of schizophrenia and is known to have an affinity for blocking D1 receptors. The drug was used to complete a 93-week double-blind crossover trial with a client displaying chronic SIB. Though clozapine is known to affect other neurotransmitter systems, the successful treatment of the participant is consistent with the D1 hypothesis of self-injurious behavior and suggests the possibility that clozapine could be an effective pharmacological intervention for some cases of SIB.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8720030     DOI: 10.1007/BF02178191

Source DB:  PubMed          Journal:  J Autism Dev Disord        ISSN: 0162-3257


  31 in total

Review 1.  Clozapine. A novel antipsychotic agent.

Authors:  R J Baldessarini; F R Frankenburg
Journal:  N Engl J Med       Date:  1991-03-14       Impact factor: 91.245

2.  Clozapine for refractory schizophrenia: an open study of 14 patients treated up to 2 years.

Authors:  J A Mattes
Journal:  J Clin Psychiatry       Date:  1989-10       Impact factor: 4.384

3.  Clozapine--deciphering the risks.

Authors:  S L Gerson
Journal:  N Engl J Med       Date:  1993-07-15       Impact factor: 91.245

4.  Aversive control of self-injurious behavior in a psychotic boy.

Authors:  B G Tate; G S Baroff
Journal:  Behav Res Ther       Date:  1966-11

5.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

6.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

Authors:  L Farde; A L Nordström; F A Wiesel; S Pauli; C Halldin; G Sedvall
Journal:  Arch Gen Psychiatry       Date:  1992-07

7.  Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.

Authors:  G R Breese; A A Baumeister; T J McCown; S G Emerick; G D Frye; K Crotty; R A Mueller
Journal:  J Pharmacol Exp Ther       Date:  1984-11       Impact factor: 4.030

8.  Clozapine antagonism of D-1 and D-2 dopamine receptor-mediated behaviors.

Authors:  H E Criswell; R A Mueller; G A Breese
Journal:  Eur J Pharmacol       Date:  1989-01-10       Impact factor: 4.432

Review 9.  Efficacy and specificity of pharmacological therapies for behavioral disorders in persons with mental retardation.

Authors:  A A Baumeister; M E Todd; J A Sevin
Journal:  Clin Neuropharmacol       Date:  1993-08       Impact factor: 1.592

10.  Problem behavior and psychiatric impairment within a developmentally disabled population I: behavior frequency.

Authors:  J W Jacobson
Journal:  Appl Res Ment Retard       Date:  1982
View more
  3 in total

1.  Brief report: effects of clozapine on self-injurious behavior of two risperidone nonresponders with mental retardation.

Authors:  R Hammock; W R Levine; S R Schroeder
Journal:  J Autism Dev Disord       Date:  2001-02

2.  Chronic metals ingestion by prairie voles produces sex-specific deficits in social behavior: an animal model of autism.

Authors:  J Thomas Curtis; Amber N Hood; Yue Chen; George P Cobb; David R Wallace
Journal:  Behav Brain Res       Date:  2010-04-28       Impact factor: 3.332

Review 3.  Clozapine versus typical neuroleptic medication for schizophrenia.

Authors:  Adib Essali; Nahla Al-Haj Haasan; Chunbo Li; John Rathbone
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.